News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Drug Appears to Prolong Survival in Stomach Cancer Patients, Seoul National University and University Hospital Gasthuisberg Study


8/20/2010 6:16:51 AM

Physorg.com -- August 19, 2010 An Article published Online First by The Lancet says that for patients with HER2-positive advanced gastric cancer, addition of tastuzumab to standard cisplatinum/fluoropyrimidine chemotherapy results in a median survival of 13.8 months, compared with 11.1 months with chemotherapy alone. This corresponds to a 26% reduction in the death rate for patients in the trastuzumab group. Thus trastuzumab combined with standard chemotherapy could be considered a new standard option for patients with this condition. However, an accompanying Comment questions the cost effectiveness of the treatment. The Article is by Professor Yung-Jue Bang, Seoul National University College of Medicine, Seoul, South Korea, and Dr Eric van Custem, University Hospital Gathuisberg, Leuven, Belgium, and colleagues.

Read at Physorg.com
Read at MSN
Read at ProPublica


comments powered by Disqus
Physorg.com
MSN
ProPublica
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES